Advertisement

European Journal of Epidemiology

, Volume 28, Issue 6, pp 485–492 | Cite as

Statin use and risk of hepatocellular carcinoma

  • Shih-Wei Lai
  • Kuan-Fu Liao
  • Hsueh-Chou Lai
  • Chih-Hsin Muo
  • Fung-Chang Sung
  • Pei-Chun ChenEmail author
PHARMACO-EPIDEMIOLOGY

Abstract

The objective of this study was to explore the association between statins use and risk of developing hepatocellular carcinoma (HCC). We used the research database of the Taiwan National Health Insurance program to conduct a population-based case–control study. Cases were 3,480 patients with newly diagnosed HCC identified during 2000 and 2009. Controls were 13,920 subjects without HCC and frequency matched for age, sex and duration of observational period of cases (i.e., the duration between year of being enrolled in the insurance program and index year of cases). Six commercially available statins, including simvastatin, lovastatin, fluvastatin, atorvastatin, pravastatin, and rosuvastatin, were analyzed. The adjusted odds ratio [OR] of HCC was 0.72 [95 % (CI) 0.59–0.88] for the group with stains use, when compared to the group with non-use of statins. In sub-analysis, simvastatin (OR 0.69, 95 % CI 0.50–0.94), lovastatin (OR 0.52, 95 % CI 0.36–0.76) and atorvastatin (OR 0.70, 95 % CI 0.53–0.93) were associated with significant reduction in odds of HCC. Statins use correlates with 28 % decreased risk of HCC. Individual statins, including simvastatin, lovastatin and atorvastatin, are associated with reduced risk of HCC.

Keywords

Hepatocellular carcinoma Statin 

Notes

Acknowledgments

The authors thank the National Health Research Institute in Taiwan for providing the insurance claims data. This study was supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004).The funding agency did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors disclose no conflicts of interest.

References

  1. 1.
    Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120:833–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008;44:2122–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121:302–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100:134–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Department of Health. Taiwan: Main causes of death in 2010. http://www.doh.gov.tw. [cited in 2012 January].
  6. 6.
    El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Chiu HF, Ho SC, Chen CC, Yang CY. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol. 2011;106:894–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30:623–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Cabibbo G, Craxi A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2010;14:352–5.PubMedGoogle Scholar
  10. 10.
    Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res. 2007;37(Suppl 2):S101–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore). 2010;89:295–9.CrossRefGoogle Scholar
  12. 12.
    Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol. 2011;106:1697–704.PubMedCrossRefGoogle Scholar
  13. 13.
    Lai SW, Su LT, Lin CH, Tsai CH, Sung FC, Hsieh DP. Polypharmacy increases the risk of Parkinson’s disease in older people in Taiwan: a population-based study. Psychogeriatrics. 2011;11:150–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107:46–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10–9.PubMedGoogle Scholar
  16. 16.
    Friis S, Olsen JH. Statin use and cancer risk: an epidemiologic review. Cancer Invest. 2006;24:413–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010;9:603–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Shih-Wei Lai
    • 1
    • 2
  • Kuan-Fu Liao
    • 3
    • 4
    • 5
  • Hsueh-Chou Lai
    • 6
    • 7
  • Chih-Hsin Muo
    • 8
    • 9
  • Fung-Chang Sung
    • 8
    • 9
  • Pei-Chun Chen
    • 10
    Email author
  1. 1. School of MedicineChina Medical UniversityTaichungTaiwan
  2. 2.Department of Family MedicineChina Medical University HospitalTaichungTaiwan
  3. 3.Institute of Integrated MedicineChina Medical UniversityTaichungTaiwan
  4. 4.Department of Internal MedicineTaichung Tzu Chi General HospitalTaichungTaiwan
  5. 5.Department of Health Care AdministrationCentral Taiwan University of Science and TechnologyTaichungTaiwan
  6. 6.School of Chinese MedicineChina Medical UniversityTaichungTaiwan
  7. 7.Department of Internal MedicineChina Medical University HospitalTaichungTaiwan
  8. 8.Department of Public HealthChina Medical UniversityTaichungTaiwan
  9. 9.Management Office for Health DataChina Medical University HospitalTaichungTaiwan
  10. 10.Institute of Epidemiology and Preventive Medicine, College of Public HealthNational Taiwan UniversityTaipeiTaiwan

Personalised recommendations